Main Menu

This technology includes a novel minigenome assay for arenaviruses that allows for high-throughput screening (HTS) of potential antiviral compounds. To complement to minigenome assay, we have also developed a technique to generate recombinant arenaviruses expressing a reporter protein to allow to HTS of antiviral compounds at BSL-4. This allows for confirmation of potential hits identified by the initial minigenome screen. Human infections with some Arenaviruses such as Lassa (LASV) and Junin (JUNV) virus can result in viral hemorrhagic fever (VHF) disease.

This technology includes an updated North American Lineage H7 (N.A H7) real-time RT-PCR assay is designed for specific detection and characterization of North American lineage of A/H7 influenza viruses. Since 1995, poultry infection with N.A lineage influenza A/H7 viruses has been greatly increasing. The outbreaks of N.A A/H7 viruses in poultry as well as wild birds occurred many times in Canada, Mexico and USA; meanwhile a number of human infection caused by N.A A/H7 viruses have been confirmed following exposure to infected poultry.

This technology includes an optimized influenza A/H5 subtyping real-time RT-PCR assay for detection and characterization of Asian lineage A/H5N1 viruses. The highly pathogenic avian influenza (HPAI) A/H5N1 viruses, first isolated in human in 1997, have spread among birds over seventy countries on three continents. In 2014 a novel reassortant HPAI A/H5N8 virus has been detected in poultry in Asia, Europe, As well as Canada and USA. In addition, genetic reassortment of this virus with circulating avian influenza viruses has resulted in the novel viral combinations.

This technology includes isolate of Middle East respiratory syndrome coronavirus (MERS-CoV) for antiviral and diagnostic development. The isolate was confirmed by full genome sequencing and further characterized by serologic and molecular testing and electron-microscopical studies. This is the first MERS-CoV strain isolated from a US imported case of MERS.

This technology includes combinations of currently approved antiretrovirals (ARVs) which could allow for simpler dosing regimens that improve adherence to HIV prevention strategies. Event-Driven PrEP (ED-PrEP) with 2 oral doses of tenofovir disoproxil fumarate (TDF)/emtricitabine (FTC) taken 2-24 hours before sex, a 3rd dose 24 hours after sex, and a 4th dose 48 hours after sex (2+1+1) is considered as a PrEP option by the World Health Organization for men who have sex with men (MSM). Recommended post-exposure prophylaxis (PEP) regimens require 28 days of daily oral dosing.

This technology includes HIV clones to develop proteomic microarrays for HIV research. The microarray chip can be used to monitor the antibody response to all proteins and many epitopes of HIV-1.

This technology includes Klebsiella pneumoniae isolate to be used for research studies and diagnostic tests to detect antimicrobial resistance.

This technology includes an Escherichia coli isolate to be used in for research purposes and the development of diagnostics. The isolate is unique because it has the mcr-1 gene.

This technology includes an isolate of the yeast species Candida auris to be used in the development of diagnostic tools or anti-fungal for therapeutic use.

This technology includes a vaccine for immunizing against different strains of rotavirus. Rotavirus is a highly contagious virus causing severe diarrhea in children and can be fatal. Due to various circumstances, the number of available, efficacious vaccines for rotavirus is declining at a time when infections remain a serious worldwide problem. This technology meets the need for vaccines against human rotavirus A strains of both common and less common types.